Silibinin inhibits F-actin assembly leading to G2/M cell cycle arrest in human breast cancer cells - is targeted therapy on the horizon?

Breast Cancer as a multi-factorial disease has been widely concerned due to its high incidence. It is urgent to find new targets to treat breast cancers. Our previous research found silibinin induced Apoptosis in both the hormone-sensitive breast Cancer cells MCF-7 and the triple-negative breast Cancer (TNBC) cells MDA-MB-231, through inhibiting the YAP pathway. Besides Apoptosis, we here discover silibinin induces G2/M cell cycle arrest in both cells, which are also dependent on the inhibition of YAP. Interestingly, the F-actin assembly is markedly reduced by Silibinin. F-actin is found to be positively regulated by YAP, due to its transcriptional regulations of factors for polymerization. Meanwhile, disturbance of F-actin assembly by using Cytochalasin D contributes to cell cycle arrest, suggesting that F-actin disassembly is not just a consequence following YAP inhibition, but also plays a critical role in modulating cell cycle arrest. Further study on the interaction of silibinin and F-actin reveals that silibinin directly targets Capza1, which causes F-actin disassembly. Moreover, promoting F-actin assembly by si-Capza1 transfection restores YAP's activity, suggesting a positive interaction between YAP and F-actin. Of note, by simultaneous transfection of si-YAP/TAZ and si-Capza1, we find that although YAP has a regulatory effect on F-actin assembly, Capza1-mediated F-actin disassembly is decisive for silibinin-induced cell cycle arrest. Our results reveal the F-actin assembly is inhibited by silibinin, and this results in G2/M cell cycle arrest in human breast Cancer cells, providing new ideas for anti-cancer therapies including TNBCs. Abbreviations: ABPs, actin binding proteins; ARP2, actin-related protein2; Capza1, capping actin protein of muscle Z-line subunit alpha 1; CDC2, Cell Division Cycle protein 2/CDK1, Cyclin-Dependent Kinase 1; CDKi, cyclin-dependent kinase inhibitors; CDKs, cyclin-dependent kinases; CETSA, cellular thermal shift assay; CFL1, cofilin 1; Cyto D, Cytochalasin D; DARTS, drug affinity responsive target stability; DIAPH3, diaphanous related formin 3; DMEM, Dulbecco's Modified Eagle medium; ER, estrogen receptor; F-actin, filamentous actin; FBS, fetal bovine serum; G-actin, globular actin; GSN, gelsolin; HER2, human epidermal growth factor receptor 2; LAMP1, lysosomal associated membrane protein 1; NLS, nuclear localization signal; PDB, protein data bank; PFN1, profilin 1; PR, progesterone receptor; qRT-PCR, quantitative real-time polymerase chain reaction; RT, room temperature; Sili, silibinin; si-RNAs, small interfering RNAs; TNBC, triple-negative breast cancer; VP, verteporfin; YAP, Yes-associated protein.

Breast cancer; Capza1; F-actin; G2/M arrest; Silibinin; YAP.